Floatz logo

Brigatinib

Epithelial Tumor

University Health Network, TorontoSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Epithelial Tumor cohort.

Asset / SponsorPhaseRating
Sorafenib
Shandong Cancer Hospital and Institute
Phase 3BB
Catumaxomab
Neovii Biotech
Phase 2/3B
Pembrolizumab
Sheba Medical Center
Phase 2B
Enadenotucirev
Akamis Bio
Phase 1/2B
Linifanib
Abbott
Phase 3B

View all 36 →

Same molecule, other indications

Brigatinib is also rated in:

cancerDormant
B
Indicative ·
63 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →